Table 2.

Differential miRNA expression between non-metastatic and metastatic OSCC samples

	Fold change (N0/N+)	P value
hsa-mir-31-5p	3.33	2.02E-002
hsa-mir-130b-5p	3.04	3.14E-002
hsa-mir-301a-3p	2.29	1.06E-001
hsa-mir-1301	−2.07	1.89E-001
hsa-mir-551b-3p	−2.10	1.60E-001
hsa-mir-345-5p	−2.22	1.37E-001
hsa-mir-30a-5p	−2.31	1.25E-001
hsa-mir-326	−2.32	1.18E-001
hsa-mir-769-5p	−2.35	1.13E-001
hsa-mir-139-5p	−2.40	1.02E-001
hsa-mir-218-5p	−2.72	6.69E-002
hsa-mir-106a-5p	−2.81	8.02E-002
hsa-mir-335-5p	−3.56	2.16E-002
hsa-mir-296-5p	−3.58	2.21E-002
hsa-mir-20b-5p	−3.88	1.54E-002
hsa-mir-23c	−4.98	4.83E-003
hsa-mir-1277-3p	−9.82	1.80E-004
hsa-mir-181d-5p	−10.01	1.66E-004

Positive Fold Change: higher expression in non-metastasized OSCC; negative Fold Change: higher expression in metastasized OSCC. p-values were adjusted using the False Discovery Rate (FDR) correction and adjusted p values < 0.05 are in bold in order to highlight statistical significance. The suffix 3p/5p indicate which of the two arms of the miRNA was considered in the analysis, being either exclusively expressed or predominantly expressed in the dataset (Additional files 2 and 3 present detailed information on the expression levels of each arm)